Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kuxin Pingni granule is a Traditional Chinese Medicine (TCM) formulation developed by the **Jiangsu Province Hospital of Integration of Chinese and Western Medicine** for the treatment of chronic heart failure (CHF). The formula is based on the TCM principle of using "bitter and acrid" (Kuxin) herbs to regulate Qi and fluid metabolism, with "Pingni" referring to the suppression of adverse Qi flow. It is typically administered as an adjunctive therapy alongside guideline-directed medical therapy (GDMT) for patients with NYHA class II–IV heart failure. Clinical evaluation of the granule focuses on its ability to improve functional capacity, enhance cardiac function (measured by LVEF), and reduce biomarkers of heart failure such as NT-proBNP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kuxin pingni granule.